Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes
- 15 March 2004
- journal article
- Published by American Society of Hematology in Blood
- Vol. 103 (6) , 2397-2400
- https://doi.org/10.1182/blood-2003-07-2209
Abstract
Sickle cell vaso-occlusion is a complex multistep process likely involving heterotypic interactions among sickle erythrocytes (red blood cells [RBCs]), leukocytes (white blood cells [WBCs]), and endothelial cells. Recent data using intravital microscopy in a sickle cell mouse model suggest that adherent leukocytes in postcapillary venules play a critical role in vaso-occlusion by capturing circulating sickle RBCs. In the course of studies to investigate the adhesion receptors mediating sickle RBC-WBC interactions, we found that control nonspecific immunoglobulin G (IgG) preparations displayed significant inhibitory activity. As a result, we studied the effects of commercial intravenous human immune globulin (IVIG) preparations and found that IVIG inhibits RBC-WBC interactions in cremasteric venules in a dose-dependent manner. IVIG of at least 200 mg/kg dramatically reduced these interactions, even after tumor necrosis factor-α (TNF-α) stimulation, and not only increased microcirculatory blood flow but also improved survival of sickle cell mice. These data raise the possibility that IVIG may have a beneficial effect on sickle cell–associated vaso-occlusion.Keywords
This publication has 25 references indexed in Scilit:
- Transgenic sickle mice have vascular inflammationBlood, 2003
- Colony-Stimulating Factor-1-Dependent Macrophages Are Responsible for IVIG Protection in Antibody-Induced Autoimmune DiseaseImmunity, 2003
- Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc ReceptorScience, 2001
- Sickle cell anemia as an inflammatory diseaseJournal of Clinical Investigation, 2000
- Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal miceJournal of Clinical Investigation, 2000
- Transgenic Knockout Mice with Exclusively Human Sickle Hemoglobin and Sickle Cell DiseaseScience, 1997
- Enhanced Levels of Soluble VCAM-1 in Sickle Cell Patients and Their Specific Increment during Vasoocclusive CrisisClinical Immunology and Immunopathology, 1996
- Post‐Transfusion Hyperhaemolysis in a Patient with Sickle Cell Disease: Use of Steroids and Intravenous Immunoglobulin to Prevent Further Red Cell DestructionVox Sanguinis, 1995
- Acute renal failure associated with immunoglobulin therapyAmerican Journal of Kidney Diseases, 1995
- High-Dose Intravenous Immunoglobulin Therapy, Blood Rheology, and Sickle Cell AnemiaPediatric Hematology and Oncology, 1993